Premium
Research of UL54‐specific siRNA on herpes simplex virus type II replication
Author(s) -
Qing Guo,
Weili Weng,
Fanqin Zeng,
Rongchang Zheng,
Yijin Luo,
Jianqun Du
Publication year - 2011
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2010.04732.x
Subject(s) - small interfering rna , herpes simplex virus , titer , transfection , vero cell , virology , virus , lipofectamine , viral replication , cell culture , biology , microbiology and biotechnology , medicine , gene , vector (molecular biology) , biochemistry , recombinant dna , genetics
To determine how UL54‐specific siRNA affects virus replication and protection of host cells, we examined virus titer and the activity of the cells at 12 hours, 24 hours, 36 hours, 48 hours, 60 hours and 72 hours after process of RNAi, including: four UL54‐specific siRNAs and the positive/negative control siRNAs synthesized in vitro by chemical processes. The Vero cells were transfected with siRNAs using lipofectamine 2000 followed by infection by HSV‐II. Our studies reveal that the groups with UL54‐specific siRNA decreased significantly in virus titer at 12–24 hours, and only slightly decreased after that; groups with UL54‐specific siRNA had higher OD values shown by MTT colorimetric assay than blank cells and survived better; R2 and R4 groups had lower virus titer and better survival than other groups. UL54‐specific siRNA can inhibit HSV‐II replication, while protecting host cells. There are effective and ineffective siRNA, which were synthesized in accordance with the same principles.